Sign In
Buy SNGX
$0.483
-0.266 (-35.48%)
At Close: Jun 03, 2026
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
01:23pm, Wednesday, 17'th Dec 2025
Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
07:30am, Wednesday, 17'th Dec 2025
Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J. , Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-st
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
08:30am, Wednesday, 03'rd Dec 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within t
50 of 80 patients enrolled in FLASH 2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J. , Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Co
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
07:30am, Friday, 07'th Nov 2025
PRINCETON, N.J. , Nov. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 14'th Oct 2025
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J. , Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stag
FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J. , Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or th
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 30'th Sep 2025
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J. , Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp
Soligenix Announces Closing of $7.5 Million Public Offering
04:05pm, Monday, 29'th Sep 2025
Cash runway extended through 2026 to fund multiple expected key inflection points PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a l
Soligenix Announces Pricing of $7.5 Million Public Offering
06:33am, Friday, 26'th Sep 2025
PRINCETON, N.J. , Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
07:30am, Tuesday, 23'rd Sep 2025
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J. , Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha
Two Year Stability demonstrated in both bivalent and trivalent configurations at temperatures of 40°C / 104°F PRINCETON, N.J. , Sept. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligeni
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:30am, Tuesday, 02'nd Sep 2025
PRINCETON, N.J. , Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Why Is Soligenix Stock Soaring On Monday?
01:03pm, Monday, 18'th Aug 2025
Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet's Disease.
Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph
